Table 1.

Ongoing and published clinical trials combining EGFR monoclonal antibodies with immunotherapeutic agents in SCCHN

DesignTitleTrial numberStatus
Phase IIA Phase I/II Study of Concurrent Cetuximab and Nivolumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell CarcinomaNCT03370276Recurrent or metastatic
Phase IIIRandomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)NCT02999087Locoregional
Phase III (terminated)Nivolumab or Nivolumab Plus Cisplatin or Cetuximab, in Combination with Radiotherapy in Patients with Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck CancerNCT03349710Locoregional
Phase IPhase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and the anti-CTLA-4 monoclonal antibody (mAb) ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC)NCT 0193592Locoregional
Phase IIMotolimod and Standard Combination Chemotherapy with Cetuximab in Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.NCT01836029Recurrent and metastatic SCCHN (manuscript published; ref. 88).
Phase IIEACH: Evaluating Avelumab in Combination with Cetuximab in Head and Neck Cancer (EACH)NCT03494322Locoregional